In vitro activity assessment of cefiderocol against Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter spp., including β-lactam nonsusceptible molecularly characterized isolates, collected from 2020 to 2021 in the United States and European hospitals

Abstract excerpt

ABSTRACT This study reports the activity of cefiderocol against Enterobacterales, Pseudomonas aeruginosa , and Acinetobacter spp. isolates collected from the United States and Europe, including Israel and Turkey, from 2020 to 2021. Among Enterobacterales, 2.8% were carbapenem nonsusceptible (CNSE); cefiderocol inhibited 96.6%/85.1% [Clinical Laboratory Standards Institute (CLSI)/European Committee on...

Topics

Join the communities discussing this publication.

• Antibiotic Resistance in Bacteria
• Antibiotic Use and Resistance
• Antibiotics Pharmacokinetics and Efficacy